CDSCO Flags 46 Drug Batches for Failing Quality Tests in July
The Central Drugs Standard Control Organization (CDSCO) has declared 46 batches of medicines as "Not of Standard Quality" (NSQ) after drug samples tested by its regional and central laboratories in July 2025 failed to meet required pharmacopeial standards.
The flagged medicines include widely prescribed formulations such as antibiotics, cardiac drugs, gastrointestinal medicines, hormonal injections, and pain relief products.
These include Azithromycin Tablets IP (Aziventis-500) manufactured by Gnosis Pharmaceuticals, Heparin Injection IP 1000 IU/ml (Flagorin) manufactured by Divine Laboratories, Amikacin Sulphate Injection manufactured by SAI Parenterals, Amoxycillin and Potassium Clavulanate Tablets I.P. 625 mg manufactured by Hindustan Antibiotics, Dexamethasone Tablets IP 4mg (Dexatore-4) manufactured by United Bioceuticals, and others.
For more details, check out the full story on the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.